Why IDEAYA Biosciences Stock Is Back in Focus

IDEAYA Biosciences (IDYA) is drawing renewed investor attention after enrolling the first patient in a Phase 1 trial that pairs IDE892 with IDE397 in MTAP-deleted solid tumors.

The study centers on cancers such as non-small cell lung and pancreatic, where MTAP deletions are relatively common and no approved targeted therapies currently exist. This development is making IDEAYA Biosciences stock a focal point for investors watching early clinical readouts.

IDEAYA Biosciences' recent IDE892 and IDE397 trial announcement sits alongside a leadership shift, with President and CEO Yujiro S. Hata also becoming Chairman. The stock has recorded a 24.7% 30 day share price return and a 64.9% one year total shareholder return, which together highlight momentum associated with both clinical and governance developments.

If you are interested in how other health focused AI drug developers are trading around key data points, this is a good moment to scan 38 healthcare AI stocks

With IDEAYA Biosciences stock up 24.7% over the past month and 64.9% over the past year, yet trading at a 45% discount to the average analyst price target, is this still a potential entry point, or is the market already pricing in future growth?

Preferred Price-to-Sales of 14.2x: Is It Justified?

At a last close of $36.30, IDEAYA Biosciences is described as good value against its peer group on one key gauge, even though it screens as expensive versus the broader US Biotechs industry on the same metric.

The preferred measure here is the price-to-sales, or P/S, ratio. For IDEAYA Biosciences, that figure sits at 14.2x, which compares to a peer average of 28.9x and an industry average of 10.9x. So the stock is priced higher than the wider US Biotechs sector on sales, but lower than its closer peer set.

This mix of signals suggests the market is assigning a premium to IDEAYA Biosciences relative to the broader industry, potentially reflecting its pipeline focus and existing collaborations, while still leaving a discount in place relative to peers that carry even richer P/S ratios. At the same time, the estimated fair P/S ratio for the company is 2.8x, which is much lower than the current 14.2x and indicates a level that the market could potentially move toward if expectations around future sales or execution reset.

Against that backdrop, IDEAYA Biosciences also screens as trading 77.7% below an internal fair value estimate based on future cash flows, with the stock at $36.30 compared with an indicated $162.42 per share. That discounted cash flow, or DCF, estimate is built by projecting future cash flows and discounting them back to today, and it can point in a very different direction to simple sales multiples when a company is expected to generate much larger cash flows further out in time.

Result: Price-to-sales of 14.2x (OVERVALUED) compared to the estimated fair ratio, but below the peer average and above the broader industry.

However, IDEAYA Biosciences also carries clear risks, including ongoing net losses of $140.059 million and uncertainty around future clinical outcomes and regulatory decisions.

Another View on IDEAYA Biosciences Valuation

The earlier P/S discussion presents IDEAYA Biosciences as expensive on sales compared with the wider US Biotechs industry, yet cheaper than its closer peers. Our DCF model, however, points the other way, with a fair value of $162.42 per share versus the current $36.30, implying the stock is materially undervalued. Which signal should matter more for you?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out IDEAYA Biosciences for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 44 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Balancing the cautious tone around risks with the interest in IDEAYA Biosciences' potential, move quickly to review both sides of the story and weigh the 2 key rewards and 1 important warning sign

Looking for more investment ideas beyond IDEAYA Biosciences?

If IDEAYA Biosciences has caught your attention, do not stop here. Use these focused stock ideas to broaden your watchlist and inform your next move.

• Target potential value opportunities by scanning 44 high quality undervalued stocks that combine attractive pricing with solid fundamental checks.
• Prioritize resilience first and review 70 resilient stocks with low risk scores to see which companies score well on financial strength and risk factors.
• Spot earlier stage opportunities by reviewing the 21 elite penny stocks with strong financials that pass quality and financial health filters.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.